Retatrutide, a novel dual-action glucose-dependent insulinotropic polypeptide receptor agonist developed by Alluvi Solutions, is sparking considerable buzz within the scientific community as a potential advancement in weight management. Initial clinical data indicate a significant influence on body mass, often exceeding current available therapies.